CTOs on the Move

Silicon Therapeutics

www.silicontx.com

 
Silicon Therapeutics is an integrated physics driven drug discovery company focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to design and optimize compounds for targets that were previously considered "undruggable." Our science, our team, and our mission are focused on applying advanced computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Huafeng Xu
 Chief Technology Officer Profile

Similar Companies

Engrail Therapeutics

Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).

Septodent

Septodent is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advance Pharmacy Services , WV

Advance Pharmacy Services , WV is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular NeuroImaging

Molecular NeuroImaging is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.